{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-23-000048","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.691792+00:00","generated_at":"2026-06-12T01:13:53.719128+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Supernus Q2 total revenues down 20% to $135.5M; Qelbree sales up 179%","bullets":["GAAP operating loss of $17.6M vs income of $11.3M in Q2 2022; net loss $0.8M ($0.02 loss per share).","Qelbree net sales $31.0M (+179% YoY), GOCOVRI $28.8M (+17%); Trokendi XR fell 73% to $19.3M on generic erosion.","Non-GAAP adjusted operating earnings of $10.0M in Q2 vs $37.6M a year ago; six-month adjusted earnings $40.5M.","Full-year 2023 guidance reaffirmed: revenues $580–620M, GAAP operating loss ($30)–($10)M, non-GAAP op earnings $75–100M.","Cash and marketable securities $189.1M at June 30; completed $402.5M convertible note and $93M credit line repayments."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-23-000048","json":"https://secwatch.observer/filing/0001356576-23-000048.json","markdown":"https://secwatch.observer/filing/0001356576-23-000048.md","text":"https://secwatch.observer/filing/0001356576-23-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000048/0001356576-23-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000048/supn-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:13:53.719128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16a7aef85ae216294f50bf9a966fee3d21151d10","claim":"SUPERNUS PHARMACEUTICALS, INC. reported the second quarter ended June 30, 2023 results: revenue $135.5 million.","evidence_excerpt":"expects to have data in the first half of 2024. Financial Highlights Total revenues For the three months ended June 30, 2023, total revenues and total net product sales were $135.5 million and $128.3 million, respectively, compared to total revenues and total net product sales of $170.1 million and $165.5 million for the same periods in 2022. For the six months","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000048/0001356576-23-000048-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$135.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"bfecbf4a0477ad06e33fecae8a7922cb02e44c7b","claim":"SUPERNUS PHARMACEUTICALS, INC. reported the first six months of 2023 results: revenue $289.3 million.","evidence_excerpt":"Total revenues of $289.3 million in the first six months of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000048/0001356576-23-000048-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first six months of 2023"},{"label":"Revenue","value":"$289.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}